√ Editorial
√ SOX2 and OCT4 in nasopharyngeal carcinoma
√ Amniotic membrane for pterygium excision
√ Retinal vascular changes after laser
√ Biomolecular changes in contact lens wear
√ Amniotic graft in infectious keratitis
√ Acute peritoneal dialysis in Nigeria
√ A cognitive screening test for children
√ Pain management in palliative care patients
√ Self-medication and health workers
√ Predictor of non-conversion pulmonary TB
√ Sleep quality, duration, and obesity
√ Pica in childhood
√ Chronic myeloid leukemia in pediatric
√ Evaluation of hospital cancer registry
√ COVID-19 pandemic stress in Indonesia
Focus and Scope

Medical Journal of Indonesia focuses on promoting medical sciences generated from basic sciences, clinical, and community or public health research to integrate researches in all aspects of human health.

This journal publishes original articles, reviews, and also interesting case reports.

Brief communications containing short features of medicine, latest developments in diagnostic procedures, treatment, or other health issues that is important for the development of health care system are also acceptable.

Correspondence articles of our own published articles are welcome.

Abstracting and Indexing

ACI; BASE; CAB Abstracts; CiteFactor; CNKI; Dimensions; DOAJ; EBSCO; Electronic Journals Library; Embase; ESCI; GARUDA; Global Health; Google Scholar; Hinari; IMSEAR; ISC; JournalTOCs; Microsoft Academics; PKP Index; Proquest; Scilit; Scopus; SINTA; Ulrichsweb Global Serial Directory; WorldCat.

Open Access Policy

Medical Journal of Indonesia is an open-access journal which provides immediate, worldwide, and barrier-free access to the full text of all published articles without charge to readers or their institutions for access. Readers have right to read, download, copy, distribute, print, search, or link to the full texts of all articles in Medical Journal of Indonesia.

Subscription

The price per volume (four printed issues): international USD 160 (surface postage included), for ASEAN countries USD 100 (surface postage included), for Indonesia IDR 400,000 (surface postage excluded).

Advertising Policy

Editorial materials will not be influenced by advertisement. Readers can criticize the advertisement by sending it to the office. Advertisement will appear in the print or online version depending on request. For all inquiries, contact the Medical Journal of Indonesia editorial office at Medical Journal of Indonesia, Education Tower 6th floor, IMERI building, Faculty of Medicine Universitas Indonesia, Jalan Salemba Raya 6, Jakarta Pusat 10430, Indonesia; tel. +6221-29189160 ext. 201605; e-mail mji@ui.ac.id.

Copyright Notice

Authors retain copyright and grant Faculty of Medicine Universitas Indonesia rights to publish the work licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s of authorship and initial publication in Medical Journal of Indonesia.
## Editorial Board Members

<table>
<thead>
<tr>
<th>Name</th>
<th>Nationality</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agnes Kurniawan</td>
<td></td>
<td>Indonesia</td>
</tr>
<tr>
<td>Bambang B. Siswanto</td>
<td></td>
<td>Indonesia</td>
</tr>
<tr>
<td>Farrokh Habibzadeh</td>
<td></td>
<td>Iran</td>
</tr>
<tr>
<td>Grace Wangge</td>
<td></td>
<td>Indonesia</td>
</tr>
<tr>
<td>Haku Hotta</td>
<td></td>
<td>Japan</td>
</tr>
<tr>
<td>Hans-Joachim Freisleben</td>
<td></td>
<td>Germany</td>
</tr>
<tr>
<td>Hans-Jürgen Mäger</td>
<td></td>
<td>Germany</td>
</tr>
<tr>
<td>Harrina E. Rahardjo</td>
<td></td>
<td>Indonesia</td>
</tr>
<tr>
<td>Inge Sutanto</td>
<td></td>
<td>Indonesia</td>
</tr>
<tr>
<td>Jeanne A. Pawitan</td>
<td></td>
<td>Indonesia</td>
</tr>
<tr>
<td>Jörg Haier</td>
<td></td>
<td>Germany</td>
</tr>
<tr>
<td>Jose R.L. Batubara</td>
<td></td>
<td>Indonesia</td>
</tr>
<tr>
<td>Knut Adermann</td>
<td></td>
<td>Germany</td>
</tr>
<tr>
<td>Laurentius A. Pramono</td>
<td></td>
<td>Indonesia</td>
</tr>
<tr>
<td>Markus Meyer</td>
<td></td>
<td>Germany</td>
</tr>
<tr>
<td>Melva Louisa</td>
<td></td>
<td>Indonesia</td>
</tr>
<tr>
<td>Nia Kurniati</td>
<td></td>
<td>Indonesia</td>
</tr>
<tr>
<td>Pradana Soewondo</td>
<td></td>
<td>Indonesia</td>
</tr>
<tr>
<td>Rianto Setiabudy</td>
<td></td>
<td>Indonesia</td>
</tr>
<tr>
<td>Saleha Sungkar</td>
<td></td>
<td>Indonesia</td>
</tr>
<tr>
<td>Sentot Santos</td>
<td></td>
<td>Germany</td>
</tr>
<tr>
<td>Sri W.A. Jusman</td>
<td></td>
<td>Indonesia</td>
</tr>
<tr>
<td>Theddeus O.H. Prasetyono</td>
<td></td>
<td>Indonesia</td>
</tr>
<tr>
<td>Vivian Soetikno</td>
<td></td>
<td>Indonesia</td>
</tr>
<tr>
<td>Wilfred C.G Peh</td>
<td></td>
<td>Singapore</td>
</tr>
</tbody>
</table>

## Associate Editors

<table>
<thead>
<tr>
<th>Name</th>
<th>Nationality</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anna M. Singal</td>
<td></td>
<td>Indonesia</td>
</tr>
<tr>
<td>Apriani Oendari</td>
<td></td>
<td>USA</td>
</tr>
<tr>
<td>Ary I. Savitri</td>
<td></td>
<td>Indonesia</td>
</tr>
<tr>
<td>Aulia Riza</td>
<td></td>
<td>Indonesia</td>
</tr>
<tr>
<td>Dicky L. Tahapary</td>
<td></td>
<td>Indonesia</td>
</tr>
<tr>
<td>Hariyono Winarto</td>
<td></td>
<td>Indonesia</td>
</tr>
</tbody>
</table>

## Assistant Editors

<table>
<thead>
<tr>
<th>Name</th>
<th>Nationality</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dania Clarisa</td>
<td></td>
<td>Indonesia</td>
</tr>
<tr>
<td>Debora Sitorus</td>
<td></td>
<td>Indonesia</td>
</tr>
<tr>
<td>Devita A. Prabowo</td>
<td></td>
<td>Indonesia</td>
</tr>
<tr>
<td>Dewi Larsaati</td>
<td></td>
<td>Indonesia</td>
</tr>
<tr>
<td>Novi A. Anggraeeni</td>
<td></td>
<td>Indonesia</td>
</tr>
<tr>
<td>Windu C. H. N. Suryaningrat</td>
<td></td>
<td>Indonesia</td>
</tr>
</tbody>
</table>

## Layout Editors

<table>
<thead>
<tr>
<th>Name</th>
<th>Nationality</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ilham Afriantsyah</td>
<td></td>
<td>Indonesia</td>
</tr>
<tr>
<td>Tsania Faza</td>
<td></td>
<td>Indonesia</td>
</tr>
</tbody>
</table>

## Production Editor

<table>
<thead>
<tr>
<th>Name</th>
<th>Nationality</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maytias Tri Pratiwi</td>
<td></td>
<td>Indonesia</td>
</tr>
</tbody>
</table>
Contents

Editorial

347 Burden of metabolic diseases in Indonesia: an even more critical issue during COVID-19 pandemic
Dicky Levenus Tahapary, Pradana Soewondo

Commentary

350 The challenges of metabolic disorders in Indonesia: focus on metabolic syndrome, prediabetes, and diabetes
Ketut Suastika

Basic Medical Research

354 Association between SOX2 and OCT4 expression and the chemoradiation therapeutic response in undifferentiated non-keratinizing nasopharyngeal carcinoma
Lisnawati Rachmadi, Kusmardi, Monik Ediana Miranda, Maria Mayella Vianney

Clinical Research

359 A randomized clinical trial of freeze-dried amniotic membrane transplantation and conjunctival-limbal graft for pterygium excision and evaluation of conjunctival inflammation marker in tears
Made Susiyanti, Manoa Panjaitan, Grace Wangge, Tjahjono Darminto Gondhowiardjo

366 Retinal vascular caliber changes after laser photocoagulation in diabetic retinopathy
Habibah Setyawati Muhiddin, Idayani Panggara, Andi Muhammad Ichsan, Budu, Emanuele Trucco, John Ellis

372 Tear hypoxia-inducible factor-1α expression, lactate dehydrogenase, and malate dehydrogenase activity changes in soft contact lens wear
Tri Rahayu, Tjahjono Darminto Gondhowiardjo, Widya Artini, Septelia Inawati Wanandi

379 Amniotic membrane transplantation for infectious corneal ulcer treatment: a cohort retrospective study
Vega Casalita, Rina La Distia Nora, Lukman Edwar, Made Susiyanti, Ratna Sitompul

386 Acute pediatric peritoneal dialysis: impact of an opt-out model and adaptable methods in a hospital in Nigeria
Michael Abel Alao, Olayinka Rasheed Ibrahim, Olajide Olusegun Abiola, Daniel Adedosu Gbadero, Adanze Onyenonachi Asinobi

392 Comparison of a set of cognitive ability screening test for primary school-aged children in Indonesia
Meitha Togas, Hartono Gunardi, Rini Sekartini, Sri Redatin Retno Pudjiati, Eef Hogervorst
Factors related to pain management adequacy in patients receiving palliative care: data from a tertiary hospital in Indonesia
Hamzah Shatri, Ratih Arionita Agung, Vera Abdullah, Dina Elita, Rudi Putranto, Mizanul Adli, Cosphiadi Irawan

Community Research

Self-medication among health care workers in a tertiary hospital in Southern Nigeria: knowledge, attitude, and practices
Ekaete Alice Tobin, Jovita Erhazele, Martha Okonofua, Chinelo Nnadi, Eucharia Ezenwanyi Nnema, George Odigie

Predictors of smear non-conversion among new-treatment pulmonary tuberculosis: a single center case-control study in Indonesia
Arulita Ika Fibriana, Muhamad Zakki Saefurrohim, Akhriyah Atsna Setiana, Mahalul Azam, Avisenna Dutha Pratama

The impact of sleep quality and duration on leptin, appetite, and obesity indices in adults
Harry Freitag Luglio Muhammad, Satwika Arya Pratama, Dian Caturini Sulistyoningrum, Maya Nurfitriani Hartono, Emy Huriyati, Yi Yi Lee, Wan Abdul Manan Wan Muda

Case Report/Series

A case of pica in childhood with intellectual disability: focus on nonpsychopharmacology management
Fransiska Kaligis, Mirza Hapsari Massarapa, Raden Irawati Ismail Marsubrin, Tjhin Wiguna

Tyrosine kinase inhibitor resistance in pediatric chronic myeloid leukemia: a case report
Mururul Aisyi, Ayu Hutami Syarif, Nur Asih, Agus Kosasih

Brief Communication

The challenge of the implementation and evaluation of hospital-based cancer registry in Indonesia’s national referral hospital
Soehartati Gondhowiardjo, Ericko Ekaputra, Achmad Randi, Vito Filbert Jayalie

Stress during COVID-19 pandemic: mental health condition in Indonesia
Fransiska Kaligis, Madhyra Tri Indraswari, Raden Irawati Ismail

Acknowledgment of Reviewers

Front Page: Central obesity. Illustration by Tsania Faza.
Contents

See the journal website for contents.
Author Index

Abdullah V............................................... (4):399–402
Abiola OO................................................ (4):386–91
Adli M................................................. (4):399–402
Adnyana IMO ........................................ (1):88–92
Agastya IGMA ......................................... (2):233–41
Agung RA ................................................ (4):399–402
Agustin T................................................ (3):283–9
Agustini S................................................ (1):26–31
Aisya M.................................................. (4):427–30
Akbar W................................................ (3):316–21
Akura B................................................ (3):250–9
Alao MA................................................ (4):386–91
Aliska G................................................ (3):332–45
Alkaff AH............................................... (2):129–35
Ambarsari CG........................................ (3):290–7
Angelina F.............................................. (3):332–45
Angelina A............................................. (1):47–52
Antariksa B............................................ (1):58–63
Ariani N................................................ (1):42–6
Ariani R................................................ (2):228–32
Ariani R................................................ (3):322–5
Arisanty R.............................................. (1):47–52
Artini W................................................ (4):371–8
Aryasa IGMA .......................................... (1):88–92
Asih N.................................................. (4):427–30
Asinobi AO........................................... (4):386–91
Avissa R................................................ (2):120–8
Azam M............................................... (4):410–6
Azami M............................................... (2):143–8
Badfar G............................................... (2):143–8
Batubara JRL ......................................... (3):250–9
Bela B.................................................. (2):120–8
Bhattarai M........................................... (2):183–9
Bionika VC.......................................... (1):58–63
Budu.................................................... (4):366–71
Burhan E.............................................. (1):11–8
Casalita V............................................ (4):379–85
Damayanti R........................................ (2):204–12
Damayani IGAPS .................................. (3):332–45
Dewi BE............................................. (3):260–7
Diana IA............................................ (3):283–9
Djatmiko W.......................................... (1):32–7
Djer MM............................................... (3):268–74
Edwar L............................................... (4):379–85
Ekaputra E........................................... (4):431–5
Elliana F............................................. (3):275–82
Elita D............................................... (4):399–402
Ellis J................................................ (4):366–71
Erhazele J.......................................... (4):403–9
Ericca I............................................... (2):117–9
Fatmawati NND................................. (1):88–92
Fibriana AI........................................... (4):410–6
Flora R............................................... (3):245–9
Gayatri A........................................... (3):332–45
Gbadero DA........................................ (4):386–91
Gondhowiardjo SA............................. (1):93–9
Gondhowiardjo TD.............................. (4):359–65
Gondhowiardjo TD.............................. (4):371–8
Gondokaryono SP.............................. (3):283–9
Gunanti............................................. (3):250–9
Gunardi H.......................................... (4):392–8
Gunawan K......................................... (3):326–31
Gunawijaya E................................. (3):305–9
Hamid ARAH....................................... (1):1–3
Hanafi AR........................................... (1):26–31
Handoko Y.......................................... (2):149–53
Harimurti GM................................. (2):228–32
Harimurti GM................................. (3):322–5
Hartono MN........................................ (4):417–21
Hasan A........................................... (2):213–21
Hendarto A......................................... (1):19–25
Hendra P........................................... (1):71–81
Hidayat E........................................... (3):290–7
Himawan LS................................. (1):283–9
Hindoro E.......................................... (2):172–82
Hogervorst E....................................... (4):392–8
Huriyati E.......................................... (4):417–21
Husnah........................................... (2):213–21
Ibrahim OR...................................... (4):386–91
Ichsan AM...................................... (4):366–71
Immanuel S...................................... (3):250–9

Index Medical Journal of Indonesia
Volume 29, January–December 2020
Rahmayunita G ...............................(3):283–9
Randi A .................................(4):431–5
Rengganis I .............................(2):190–7
Rinaldi I .................................(2):198–203
Roebiono PS ..........................(2):228–32
Roebiono PS ..........................(3):332–5
Rosana Y ...............................(3):316–21
Rustamadji P ........................ (1):53–7
Saefurrohim MZ .........................(4):410–6
Saekhu M ..............................(3):326–31
Safitri Y .................................(3):332–45
Saifuddin A ............................(2):190–7
Sakidjan I ..............................(2):228–32
Sakidjan I ..............................(3):322–5
Salawati L ..............................(2):213–21
Salisu T .................................(1):100–9
Samoeedo E ............................(1):58–63
Santoso LA ..............................(2):154–63
Saraswati LD ........................... (1):82–7
Sari HD .................................(1):32–7
Sary LD .................................(3):332–45
Sasmono RT ............................(2):129–35
Sastroasmo S ........................... (1):19–25
Satari HI .................................(1):19–25
Satari HI .................................(3):250–9
Sekartini R .............................(4):392–8
Sembiring AA ...........................(2):228–32
Setiabudy R ............................(2):113–4
Setiana AA .............................(4):410–6
Setianingsih I ..........................(1):19–25
Setiawan CH ..........................(1):71–81
Setiawan MI ............................(2):164–71
Shatri H .................................(2):190–7
Shatri H .................................(4):399–402
Shoraya N ..............................(3):283–9
Shrestha TR ............................(2):183–9
Siagian SN .............................(2):228–32
Siagian SN .............................(3):322–5
Siane A .................................(3):332–45
Simorangkir DS .........................(3):332–45
Singka EJ .............................. (2):117–9
Sinulingga DT ..........................(1):26–31
Siregar NC .............................(1):47–52
Siregar NC .............................(3):326–31
Siste K .................................(2):233–41
Sitompul R ............................(4):379–85
Sjatha F .................................(3):260–7
Soetandyo N ........................... (1):26–31
Soewondo P ............................(4):347–9
Somasetia DH .........................(3):250–9
Storey JD ..............................(2):204–12
Suastika K .............................(4):350–3
Sudewi AAR ..........................(1):88–92
Sugito TL ..............................(3):283–9
Suhadi R ...............................(1):71–81
Suharlim E .............................(1):93–9
Sukirno ..................................(3):245–9
Sulistyo H .............................(1):32–7
Sulistyo ningrum DC ..................(4):417–21
Suryaningrat WCHN ...................(1):3–5
Susanto AD ............................(1):8–10
Susanto AD ............................(1):58–63
Susanto E ...............................(1):93–9
Susanto H ..............................(2):164–71
Susilawathi NM .......................(1):88–92
Susiyanti M ............................(4):359–65
Susiyanti M ............................(4):379–85
Suwirtri NPE ..........................(3):305–9
Syafil RA ..............................(3):310–5
Syarif AH ..............................(4):427–30
Tahapary DL ...........................(4):347–9
Tambunan USF ........................ (2):129–35
Tanter S .................................(2):172–82
Tanti I .................................(1):42–6
Tarini NMA ............................(1):88–92
Tobin EA ...............................(4):403–9
Togas M ...............................(4):392–8
Toyoshima H ..........................(3):283–9
Tresnaningtyas SA .....................(3):260–7
Tridianjari DK .........................(1):82–7
Trucco E .............................. (4):366–71
Tumbelaka MK ........................(2):222–7
Udyiyono A ............................(1):82–7
Vianney MM ...........................(4):354–8
Virginia DM ...........................(1):71–81
Wahyuni T ............................(1):64–70
Wanand SI .............................(4):371–8
Wangge G ..............................(3):243–4
Wangge G ..............................(4):359–65
Wibisana IGNG .......................(3):298–304
Wibowo J .............................(1):53–7
Wibowo N .............................(1):38–41
Wibowo N .............................(2):149–53
Widiasari NPA .........................(1):88–92
Widiastuti .............................(2):213–21
Wijdaja FF .............................(1):3–5
Subject Index

acute kidney injury ............................................ (4):386–91
addictive behavior ........................................... (2):233–41
adequacy factors ............................................. (4):399–402
adrenal insufficiency ........................................ (3):250–9
aerobic exercise .............................................. (3):245–9
air pollution ................................................... (1):11–8
alcian blue ...................................................... (1):53–7
alveolar .......................................................... (1):47–52
amniotic membrane ......................................... (4):359–65
amniotic membrane ......................................... (4):379–85
anaerobic exercise .......................................... (3):245–9
APOBEC3G ..................................................... (2):120–8
appetite .......................................................... (4):417–21
asthma ........................................................... (2):190–7
atrial septal defect .......................................... (2):228–32
atrial septal defect .......................................... (3):322–5
autoimmunity .................................................. (1):100–9
behavior ........................................................ (4):422–6
birth weight ..................................................... (1):38–41
blood pressure ............................................... (1):71–81
body mass index ............................................. (1):71–81
bone substitute .............................................. (2):136–42
breast cancer ............................................... (1):32–7
breast neoplasm ............................................ (3):298–304
cancer .......................................................... (4):43–1
carbon monoxide .......................................... (1):58–63
cardiac catheterization .................................... (3):322–5
cardiovascular ................................................ (1):71–81
catheterization .............................................. (2):228–32
catheterization .............................................. (3):305–9
chemokines .................................................... (2):129–35
chemotherapy .............................................. (1):26–31
chikungunya virus .......................................... (2):129–35
child ............................................................... (2):154–63
child ............................................................... (3):290–7
child ............................................................... (4):392–8
child ............................................................... (4):422–6
children ......................................................... (1):19–25
children ......................................................... (4):427–30
chronic myeloid leukemia ................................ (4):427–30
chronic pain ................................................... (1):42–6
codon usage .................................................... (2):120–8
cognition ........................................................ (4):392–8
colorectal cancer ............................................ (2):183–9
complication .................................................. (3):268–74
contact dermatitis .......................................... (3):290–7
contact lenses ............................................... (4):371–8
contraception ............................................... (2):204–12
cord blood ..................................................... (2):149–53
cornea ............................................................ (4):371–8
corneal perforation .......................................... (4):379–85
cotrimoxazole ............................................... (3):316–21
COVID-19 ..................................................... (3):332–45
COVID-19 ..................................................... (4):437–42
cuttlefish bone ............................................... (2):136–42
cytokines ........................................................ (2):129–35
cytotoxicity tests ............................................ (2):136–42
dengue ........................................................... (3):260–7
dengue virus .................................................. (2):129–35
diabetes mellitus ............................................. (1):82–7
diabetic retinopathy ......................................... (4):366–71
digestive surgery ............................................. (3):310–5
disasters ......................................................... (1):11–8
eating behavior ............................................. (1):71–81
efficacy .......................................................... (3):283–9
eligibility ....................................................... (2):198–203
embryonal ...................................................... (1):47–52
encephalitis ................................................... (2):154–63
end-stage renal disease ................................ (3):290–7
erectile dysfunction ....................................... (1):82–7
exacerbation .................................................. (2):190–7
exhalation ...................................................... (1):58–63
favipiravir ...................................................... (3):332–45
foodborne disease ......................................... (1):88–92
forest fire ........................................(1):58–63
growth and development ...................... (4):392–8
health care workers ............................ (4):403–9
hepatocytes .......................................... (3):260–7
high protein ........................................ (1):19–25
histology ............................................. (1):26–31
hospitals ............................................ (4):431–6
household ........................................... (1):64–70
hydroxychloroquine ............................... (3):322–45
hyperglycemia ...................................... (1):100–9
hypoaxia ............................................ (4):371–8
hypoaxia-inducible factor 1 ...................... (4):371–8
immunohistochemistry .......................... (2):183–9
in vitro .............................................. (3):260–7
in-hospital mortality .............................. (2):172–82
incidence ........................................... (3):310–5
Indonesia ............................................... (1):42–6
Indonesia ............................................ (1):58–63
Indonesian Family Life Survey 2014 ........... (2):213–21
infant .................................................. (3):322–5
infection ............................................. (3):290–7
infectious keratitis .................................. (4):379–85
inpatients .......................................... (3):316–21
insulin ............................................... (1):100–9
intelligence ........................................ (4):392–8
intercostobrachial .................................. (3):298–304
interleukin-1 ........................................ (3):250–9
interleukin-6 ........................................ (3):250–9
interleukin-6 ........................................ (4):359–65
internet .............................................. (2):233–41
intra-axial mass ..................................... (1):93–9
kyphosis .......................................... (3):326–31
lactate dehydrogenase ............................ (4):371–8
laminectomy ......................................... (3):326–31
laser photoagulation ............................... (4):366–71
leprosy ............................................. (1):64–70
leptin ................................................. (4):417–21
less developed countries ......................... (4):386–91
liquid meal replacement nutrition ................. (3):275–82
liver .................................................. (3):260–7
long follow-up ..................................... (1):93–9
long-acting reversible contraception ............ (2):204–12
lopinavir ............................................. (5):332–45
low glycemic index ................................ (3):275–82
lung cancer .......................................... (1):26–31
lung function ........................................ (1):58–63
lymph node metastases .......................... (1):32–7
lymphovascular space invasion .................. (1):32–7
macrophage migration inhibition factors ........... (3):250–9
malate dehydrogenase ............................ (4):371–8
male .................................................. (1):82–7
maternal nutrition ................................ (1):38–41
medulloblastoma .................................. (1):93–9
meningitis ......................................... (1):88–92
methylene blue ..................................... (3):298–304
microbiological techniques ...................... (4):241–6
milk proteins ....................................... (2):164–71
mismatch repair .................................... (2):183–9
monocytes ......................................... (3):260–7
mononuclear leukocytes ......................... (2):129–35
mortality rate ...................................... (2):143–8
mucin ............................................... (1):53–7
mucinous carcinoma ............................... (1):53–7
muscles ............................................. (2):164–71
MutL homolog 1 .................................... (2):183–9
MutS homolog 2 .................................... (2):183–9
mycobacterium ..................................... (4):410–6
Mycobacterium leprae ............................. (1):64–70
nasopharyngeal carcinoma ........................ (4):354–8
neonatal intensive care unit ...................... (2):143–8
neutrophil-to-lymphocyte ratio .................... (2):172–82
obesity ............................................ (2):213–21
obesity ............................................ (4):417–21
OCT4 .............................................. (4):354–8
opt-out model ...................................... (4):386–91
oseltamivir ......................................... (3):332–45
outcome assessment ............................. (1):19–25
outpatients ........................................ (3):316–21
pain management ................................ (4):399–402
palliative care ..................................... (4):399–402
pancreas ........................................... (1):100–9
pandemic .......................................... (4):347–42
panic ................................................. (4):347–42
patent ductus arteriosus .......................... (3):305–9
pedicle screws ..................................... (2):222–7
periodic acid-Schiff reaction .................... (1):53–7
peritoneal dialysis ................................ (4):386–91
peritonitis ......................................... (3):290–7
pica .................................................. (4):422–6
pilgrims ............................................ (2):198–203
placenta .......................................... (2):149–53
polymerase chain reaction ...................... (1):64–70
polymerase chain reaction ...................... (1):88–92
pornography ....................................... (2):233–41
preeclampsia ..................................... (2):149–53
pregnancy outcome ............................. (1):38–41
pregnant women.................................(2):228–32
premature birth.................................(2):143–8
prevalence ...........................................(4):403–9
prognosis ............................................(1):26–31
prognostic factor .................................(1):47–52
prokaryote gene expression .................(2):120–8
pterygium ..........................................(4):359–65
pulmonary tuberculosis .........................(4):410–6
recurrence ..........................................(1):93–9
registries ..........................................(4):431–6
remdesivir .........................................(3):332–45
respiratory tract infections .................(1):11–8
retinal vascular caliber ..........................(4):366–71
rhabdomyosarcoma ................................(1):47–52
risk ......................................................(1):71–81
risk factors .........................................(2):154–63
risk factors .........................................(2):190–7
risk factors .........................................(3):310–5
safety ...................................................(3):283–9
schwannoma .......................................(3):326–31
scoliosis .............................................(2):222–7
seizures ...............................................(2):154–63
self-medication ...................................(4):403–9
sentinel lymph node biopsy .................(3):298–304
sepsis ...............................................(1):19–25
septic shock .......................................(3):250–9
serum ................................................(2):149–53
sexual online ......................................(2):233–41
sleep duration ...................................(4):417–21
sleep quality ......................................(4):417–21
smoking ............................................(2):213–21
soccer ..............................................(2):164–71
SOX2 .................................................(2):164–71
STEMI ..............................................(4):354–8
Streptococcus suis ..............................(1):88–92
stress ...............................................(4):437–42
super-absorbent diaper ......................(3):283–9
surgery ............................................(3):268–74
surgical site infection .........................(3):310–5
teenagers .........................................(1):71–81
temporomandibular disorders ..........(1):42–6
therapy ..............................................(4):422–6
transcatheter .....................................(3):268–74
transesophageal echocardiography .......(2):228–32
treatment outcome .........................(3):305–9
tuberculosis ........................................(2):198–203
tumor necrosis factor-alpha ...............(3):250–9
tumor stage .......................................(1):32–7
type 1 diabetes mellitus ......................(1):100–9
type 2 diabetes mellitus ......................(3):275–82
tyrosine kinase inhibitor ......................(4):427–30
urinary tract infections ......................(3):316–21
ventricular septal defect ......................(3):268–74
vitamin D ...........................................(2):149–53
volcanic eruptions ..............................(1):11–8
wildfires ............................................(1):11–8
Wilms tumor ....................................(1):47–52
xenograft ..........................................(2):136–42
Zika virus .........................................(2):129–35
β-endorphin .....................................(3):245–9
Submission
The submitted manuscript should be addressed to Editor-in-chief of the Medical Journal of Indonesia. Manuscript must be submitted through online submission (http://mji.ui.ac.id/journal/index.php/mji/about/submissions) by registered users. You can easily register in the journal system. For further question contact us at mji@ui.ac.id.

General Principles
As a basic requirement, all articles submitted to the Medical Journal of Indonesia must be original work, which has never been published previously and is submitted exclusively to the Medical Journal of Indonesia. They must be written in the format of “Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals” (http://www.icmje.org/), which was established by the International Committee of Medical Journal Editors (ICMJE) and updated in December 2018. The Editorial Board reserves the right to edit all articles in aspects of style, format, and clarity. Authors may be required to revise their manuscripts for reasons of any aspect. Manuscripts with excessive errors in any aspect may be returned to authors for retyping or may be rejected. All manuscripts will be subjected to peer and editorial review.

We accept types of articles: (1) original articles: basic medical research, clinical research, or community research; (2) case report; (3) review article; (4) brief communication; (5) correspondence. Authors must also supply:

ICMJE conflicts of interest statement form (http://mji.ui.ac.id/journal/public/journals/i/coi_disclosure.pdf) (if there is any difficulties in accessing the form, you can directly visit http://www.icmje.org/conflicts-of-interest/);

copy of ethical approval (for all researches involving human and animal); and

final checklist (http://mji.ui.ac.id/journal/public/journals/i/FinalChecklist.pdf) signed by all author(s).

A cover letter should be provided along with the submission addressed to the Editor-in-chief of Medical Journal of Indonesia, which should include a statement about all previous submissions of the manuscript and previous reports that might be regarded as redundant publication of the work. If the manuscript has been submitted previously to another journal, authors are encouraged to provide previous comments along with the responses to accelerate the review process. Author(s) also have to mention the work whether it has been presented in a congress/conference/seminar.

Templates are available for original articles on http://mji.ui.ac.id/journal/public/journals/i/template1.dot and case report on http://mji.ui.ac.id/journal/public/journals/i/template2.dot for case reports.

All articles must be conformed with the international standard guidelines which can be found in equator-network.org, for example: randomized controlled trial – CONSORT, observational studies – STROBE, systematic review and meta-analysis – PRISMA, case report – CARE, and so on.

Study Ethics
All submitted papers containing animal experiments and/or involving human subjects should have obtained approval from an independent ethics committee. The copy of approval should be provided to editorial office as mentioned above.

Informed Consent
For each article published in the Medical Journal of Indonesia (MJI) an informed consent should be obtained from each participant. Informed consent consists of written permission granted by a patient or a patient’s relative on his/her behalf to publish any information, image, or case report associated to the patient’s clinical condition on the MJI. The informed consent and patient confidentiality policies are in compliant with all relevant regulations regarding data/privacy protection and the Fourth Amendment 1945 Constitution of the Republic of Indonesia, Article 28(G).

The contents of patient consent form should be adjusted to the local regulations in which the study was conducted. The author must indicate, in the main text of the manuscript, whether informed consent was obtained, including consent to publish the study a patient enrolled in. The author may be requested by the journal’s editor to submit the consent form. In some circumstances, informed consent requirement may be exempted for studies. The decision to require or waive informed consent must come from the ethics committee that reviewed and approved the study. For studies in which informed consent is waived, the author must submit the official approval letter from the ethics committee that indicates the waiver.

All identifiers, including but not limited to names, initials, dates of birth, medical record numbers, must be removed from the patient’s data or information published on the manuscript.

On the submitted and published manuscripts, the patient’s face must be blurred or, when applicable, the patient’s eyes are concealed with black bars. Images, including from ultrasound results, conventional radiography, computed tomography images, pathology images, or images taken during a surgery, must be deidentified.

Absence of a patient consent form for appropriate study will result in the submission rejection.
Publication Ethics

The publisher of this journal is a member of Committee on Publication Ethics (COPE). This journal follows guidelines from COPE in facing all aspects of publication ethics and, in particular, how to handle cases of research and publication misconduct. All articles in this journal involving human subjects should respect principles of research ethics as described in Declaration of Helsinki and studies involving animals should obey the International Guiding Principles for Biomedical Research as developed by the Council for International Organization of Medical Sciences (CIOMS).

Medical Journal of Indonesia adapts COPE principle to meet high quality standard of ethics for publisher, editors, authors, and reviewers. As an essential issue, publication ethics needs to be explained clearly to improve the quality of the research worldwide. In this part, we explain the standard for editors, authors, and reviewers. In addition, publisher does not have the right to interfere with the integrity of the contents and only support to publish in timely manner. MJII also uses similarity check for plagiarism detection.

Clinical Trial Registration

The authors are encouraged to register all clinical trials to the publicly accessible registration in any registry as recommended by ICMJE or integrated to WHO International Clinical Trials Registry Platform (ICTRP) (https://www.who.int/ictrp/network/primary/en/) or in ClinicalTrials.gov, which is a data provider to the WHO ICTRP. The trial registration number should be provided at the end of the abstract. The registration should be done prior to the conduct of the trial.

Structure and Language

Articles will be published in US English, following American spelling. Articles in English that are linguistically inadequate may be rejected. Manuscripts should be written double-spaced in all parts of the manuscript using Times New Roman 12, with margin of 2.54 cm of all sides. Articles must be submitted in the following structural order: title page and authorship, abstract, keywords, text, conflicts of interest, acknowledgments (if any), funding sources, references, tables, figures, and legends (if any).

Title Page and Authorship

The Title Page should contain: title of the article (concise, no abbreviations, maximum 16 words); full names of authors (without academic title); author’s affiliation [name(s) of department(s) and institution(s)]; disclaimers (if any); corresponding author’s name, mailing address, telephone and fax numbers, and e-mail address of the author responsible for correspondence about the manuscript (institution specific address and e-mail address of the corresponding author will be published along with the article); source(s) of support in the form of grants, equipment, drugs, or all of these (if any); short running title [maximum 40 characters (letter and spaces)]; word counts [a word count for the text only (excluding abstract, acknowledgments, tables, figure legends, and references)]; number of figures and tables; and conflict of interest declaration for each author.

Authorship of articles should be limited to those who have contributed sufficiently to take public responsibility for the contents. This includes (a) conception and design, or analysis and interpretation of data, or both; (b) drafting the article or revising it critically for important intellectual content; (c) final approval of the version to be published; (d) and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Contributors who meet fewer than all four criteria above should be listed in acknowledgment and the contributions should be specified. Corresponding authors should assure the permission of all acknowledged individuals written in the acknowledgment.

Abstract and Keywords

The abstract should be prepared in English with a structured abstract maximum 250 words for biomedical, clinical, and community research articles; and unstructured maximum 150 words for case report, brief communication, and review article. They should be concise and precise with enough information, highlighting the points and importance of the article which contains: one or two sentences of background, purpose of study; methods (basic procedures, study subject selection, observational, and analytical methods); main findings or results; and principal conclusion. Keywords are limited to 3–6 words or short phrases that will allow proper and convenient indexing. They should be obtained from Medical Subject Headings (MeSH®) (https://meshb.nlm.nih.gov/search) thesaurus produced by National Library of Medicine.

Main Text

The text should be structured as introduction, methods, results, and discussion (IMRAD). Methods should provide clarity about how, why, and when the study was done. The methods section should include the statement of approval by local, regional, or national review board. It should also clearly describe the selection of the study’s participants. Equipment used should be identified in methods by specifically giving the manufacturer’s name and address in parentheses. Give references to established methods. Conclusion should be stated at last sentence in the discussion. Footnotes are not advisable; their contents should rather be incorporated into the text. Use only standard abbreviations; use of nonstandard abbreviations can be confusing to readers. Avoid abbreviations in the title of the manuscript. The spelled-out abbreviation followed by the abbreviation in parenthesis should be used on first mention unless the abbreviation is a standard unit of measurement. If a sentence begins with a number, it should be spelled out. Cite in numerical order every reference, figure, and table. Use Arabic numerals in superscript to cite references in National Library of Medicine style.
Statistical Methods

All statistical methods used should be described in detail in the methods section of the manuscript. Avoid relying solely on statistical hypothesis testing, such as p values, which fail to convey important information about effect size and precision of estimates. Define statistical terms, abbreviations, and most symbols. Specify the computer software and version used.

Conflicts of Interest

Conflicts of interest should be transparent as detail as possible as provided in the ICMJE form as a standardized authors’ disclosures. Financial and personal relationships are easily identifiable that might bias or be seen to bias the work. Funding sources for the work should be described specifically with explanations of the role of those sources and the authors should declare that the supporting sources had no involvement in specific role. The authors should declare that the authors had access to all the study and the sponsors did not intervene the data or the work. Each author should submit a separate form from ICMJE.

Acknowledgments

Personal acknowledgments should be limited to appropriate professionals who contributed to the paper, including technical help and financial or material support, also general support by a department chairperson.

Funding Sources

Funding sources for the work should be described specifically with explanations of the role of those sources and the authors should declare that the supporting sources had no involvement in nor influence on the content of the manuscript. This statement should be written separately and limited to the funding for the work. If funder(s) had any impact into or influence on the design; data collection, management, analysis and interpretation of the data, the preparation, review, or approval of the manuscript or the decision to submit the manuscript for publication, their role must be disclosed as appropriate professionals who contributed to the paper, also general support by a department chairperson.

Tables and Figures

Total number of Table and figures are advisably not to exceed 6 in number. Tables and its title should be presented in separate sheets. Tables should be numbered in Arabic numerals, captions should be brief, clearly indicating the purpose or content of each table. Provide a footnote to each table, identifying in alphabetical order all abbreviations used. Number tables consecutively in the order of their first citation in the text and supply a brief title for each. Do not use internal horizontal or vertical lines. Give each column a short or an abbreviated heading. Explain all nonstandard abbreviations and explanatory matters in footnotes, and for explanatory matters use the following symbols, in sequence: *, †, ‡, §, ¶, **, ††, ‡‡, §§, ¶¶, etc. Identify statistical measures of variations, such as standard deviation and standard error of the mean. Be sure that each table is cited in the text. If you use data from another published or unpublished source, obtain permission and acknowledge that source fully.

Figures should be either professionally drawn or photographed, and submitted in a format (JPEG or TIFF) in the following resolutions [gray-scale or color in RGB (red, green, blue mode) at least 300 dpi (dots per inch). For x-ray films, scans, and other diagnostic images, as well as pictures of pathology specimens or photomicrographs, send sharp, glossy, black-and-white or color photographic prints, usually 127 × 173 mm (5 × 7 inches). Write the word “top” on the back of each figure at the appropriate place. Figures should be made as self-explanatory as possible, titles and detailed explanations belong in the legends-not on the figures themselves. Photomicrographs should have internal scale markers. Symbols, arrows, or letters used in photomicrographs should contrast with the background. When symbols, arrows, numbers, or letters are used to identify parts of the illustrations, identify and explain each one clearly in the legend. Explain the internal scale and identify the method of staining in photomicrographs. Photographs of potentially identifiable people must be accompanied by written permission to use the photograph.

Tables and figures should be numbered consecutively according to the order in which they have been cited in the text. If a figure has been published previously, acknowledge the original source and submit written permission from the copyright holder to reproduce it. Permission is required irrespective of authorship or publisher except for documents in the public domain using license of CC BY SA. Color figures are allowed in special circumstances, provided that the author is willing to cover the cost of reproduction. If the original size of the figures is too large, you can provide us lower quality figures on submission and good quality figures after the acceptance of the manuscript.

Units of Measurement

For measurements use both local and S.I. (System International) units. Measurements unit should be abbreviated (e.g. mm, kcal, etc.) in accordance with the Style Manual for Biological Sciences and using the metric system. Measurements of length, height, weight, and volume should be reported in appropriate scientific units. Temperatures should be in degrees Celsius. Blood pressures should be in millimeters of mercury (mmHg). Drug concentrations may be reported in either SI or mass units, but the alternative should be provided in parentheses where appropriate.

Abbreviation

Use only standard abbreviations; use of nonstandard abbreviations can be confusing to readers. Avoid abbreviations in the title of the manuscript. When first mentioned, all abbreviations must be spelled out.
followed by the abbreviation in parenthesis, unless the abbreviation is a standard unit of measurement. Abbreviations must be spelled out when first mentioned in the abstract and main text. If a sentence begins with a number, it should be spelled out except in abstract.

References

References are advisably not to exceed 25 in number but not less than 10, and should in general be limited to the last decade. Reference exceed than 25 may be accepted when it is necessary. References must be numbered in the order in which they are mentioned in the text. Use the style of the examples below, which are based on the International Committee of Medical Journal Editors (ICMJE) Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals: Sample References (http://www.nlm.nih.gov/bsd/uniform_requirements.html). The titles of journals should be abbreviated according to the style used for MEDLINE (www.ncbi.nlm.nih.gov/nlmcatalog/journals).

Avoid using abstracts as references. Information from manuscripts submitted but not yet accepted should be cited in the text as “unpublished observations” with written permission from the source. Papers accepted but not yet published may be included as references; designate the journal and add “Forthcoming”. Avoid citing “personal communication” unless it provides essential information not available publically, name the person and date of communication, obtain written permission and confirmation of accuracy from the source of personal communication. Authors is recommended to use reference management software, in writing the citations and references such as: Mendeley®, Zotero®, EndNote®, and Reference Manager®.

Here are some examples of the references:

1. Standard journal article
   Up to six authors, list all the authors.
   More than six authors, list the first six authors, followed by et al.
   Optional addition of a database’s unique identifier for the citation: [Edited 12 May 2009]
   Optional addition of a clinical trial registration number: [Added 12 May 2009]

As an option, if a journal carries continuous pagination throughout a volume (as many medical journals do) the month and issue number may be omitted.

2. Chapter in a book

3. Homepage/Web site [Edited 12 May 2009]

Editorial Process

The submitted manuscript will be checked by an editor for its suitability with Medical Journal of Indonesia’s focus and scope and for major methodological flaws within two weeks. Staff will work with the author to fulfill all the requirements within two weeks. Every submitted manuscript which passes this step will then be checked for plagiarism by Similarity Check. The manuscript needs to be re-worked if indicated for minor plagiarism and will be rejected if indicated for major plagiarism. Then, an editor-in-chief and an editorial assistant will be assigned for the manuscript. In this stage, the manuscript will be assessed based on novelty and adherence to reporting guidelines. Subsequently, the manuscript will go through peer-review process. The revisions may be required and will be re-evaluated by the editor-in-chief after the authors providing sufficient responses. The manuscript will be passed to the editor-in-chief for any further revision and ultimately will take an editorial decision. The accepted manuscript will be sent to copy-editing stage for correction of grammar and spelling errors, standardizing the journal in-house style, improving table, figure, and writing quality. The incomplete revision of this stage will result in pending scheduled publication. Then, the manuscript will enter production stage for typesetting. A pdf file is sent to the author for review and there should be no more scientific revision. A failure to comply will result in a delay of the publication since it needs editor confirmation for the changes. It will be scheduled for publication after the payment has been received. The final approval is needed from the corresponding author before it is published. The manuscript submitted by one of the editorial team of the Medical Journal of Indonesia will be processed by other editorial board members who do not have any conflict of interest with the manuscript and follow the same editorial process.

Peer Review

All submitted manuscripts (except editorial, commentary, and correspondence) in Medical Journal of Indonesia
undergo double blind peer review by at least two reviewers. All manuscripts are sent to the reviewers anonymously. Reviewers’ comments are also sent anonymously to the corresponding author to take the necessary actions and responses. All the reviewers are subjected to submit their evaluation not more than six weeks. Medical Journal of Indonesia staff ensure that the referee reports are complete. In some occasions, the review process needs more time to seek the appropriate reviewers.

**Correction and Retraction Policies**

Medical Journal of Indonesia is committed to publish Correction (Errata and Corrigenda) or Retraction dependent on the situation and in accordance with the COPE Retraction Guidelines. In all cases, these notices are linked to the original article.

**Correction** consist of errata and corrigenda. **Errata** provide a means of correcting errors that occurred after proofreading process. This includes writing, typing, editing, or publication (e.g., a misspelling, a dropped word or line, or mislabeling in a figure) of a published article. The authors need to send direct email to the editorial office (mji@ui.ac.id) to ask for an erratum and the correction will be taken based on the last proofread provided. **Corrigenda** provides a means of correcting errors that are made by the authors but the errors should not alter the overall basic results or conclusions of a published article. Note that the addition of new data is not permitted. For corrections of a scientific nature or issues involving authorship, all disputing parties must agree, in writing, to publication of the Correction. For omission of an author’s name, letters must be signed by the authors of the article and the author whose name was omitted. The editor who handled the article will be consulted if necessary. Medical Journal of Indonesia followed COPE Retraction Guidelines for **Retraction**.

**Publication Fee**

This journal only charges the article publication fee for all manuscript types, without any submission fee. The publication fee is US$ 300 for foreign authors and IDR 3,000,000,- for Indonesian authors. For each printed page that contains colored figure, you will be asked to pay US$ 50 (IDR 500,000,-) more of each printed page. Authors who want to publish Corrigenda need to pay an additional charge of US$ 50 (IDR 500,000,-) per each printed page. After the manuscript has been proofread by the corresponding author, Medical Journal of Indonesia office will send the invoice and the payment needs to be completed before being appeared online.

To enhance the research in health program, Medical Journal of Indonesia will cover the publication fee of authors from the countries that are included in group A and group B countries of HINARI by WHO. Waiver of payment is not only limited to those countries. All authors may ask a waive, and they need to send letter of waiver to editor-in-chief explaining the importance of the study and why author(s) need to be waived. The decision is made prior to the process of the review and it is the editors’ privilege to approve or reject the request.

**Copyright Notice**

Authors retain copyright and grant Medical Journal of Indonesia rights to publish the work licensed under a Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/) that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia. Authors are permitted to copy and redistribute the journal’s published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.

You may not make commercial use of any article, without our prior written consent and payment of the appropriate fees, even if you are the author or the employer, funder or affiliate organization of the author of the article. For the purposes of these Terms, “commercial use” means use in any manner that is primarily intended for or directed toward commercial advantage or monetary compensation, including but not limited to provisions or distribution of any article or part any article (including any abstract, figures or tables) in any format: to support marketing activities; in response to medical information requests; to support activities at a conference, exhibition or trade show; as resource material on a company or product-specific website. You may contact to our office at mji.ui.ac.id.

Updated - July 2020
Title of article: ________________________________________________________________

1. Manuscript Preparation
   The author(s) hereby affirm that I do substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND drafting the work or revising it critically for important intellectual content; AND final approval of the version to be published; AND agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The author(s) affirm that the material has not been previously published and that the author(s) have not transferred elsewhere any rights to the article. The author(s) have checked the manuscript to comply with the instructions for authors of Medical Journal of Indonesia and agreed to contribute for publication fee.

2. Informed Consent
   The author(s) haven’t suggested any personal information that may make the identity of the patient recognizable in any forms of description part, photograph or pedigree. When the photographs of the patient were essential and indispensable as scientific information, the author(s) have received the consent in writing form and have clearly stated it.

3. Human and Animal Right
   In case of experimenting on human, the author(s) have certified that the process of the research is in accordance with ethical standards of Helsinki declaration, domestic and foreign committees that preside over human experiment. If any doubts is raised whether the research was proceeded in accordance with the declaration, the author(s) would explain it. In case of experimenting on animals, the author(s) have certified that the author(s) had followed the domestic and foreign guideline related to experiment of animals in a laboratory.

4. Permission Approvals
   The author(s) have received consent from the author or editor the picture or the table that was quoted from other journals or books. A portion or entire of the article hasn’t been published on other journals nor contributed to other journals and under review.

5. Copyright Notice
   The author(s) retain copyright and grant Faculty of Medicine Universitas Indonesia rights to publish the work licensed under a Creative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/4.0/). Further information of this topic is available on http://mji.ui.ac.id/journal/index.php/mji/copyright.

6. Disclosure of Conflict of Interest
   The author(s) of the journal have clarified everything that interest may arise such as work, research expenses, consultant expenses, and intellectual property on the document of ICMJE form disclosure of conflicts of interest.

Author’s Name: ___________________________ Signature: ___________________________ E-mail: ___________________________ Date: ___________________________

Notes: This form must be signed by all authors in order as appeared in the article.